Methods: Eighteen patients fit inclusion criteria of having a systemic reaction to AIT between 11/1/12 and 10/31/14. Controls (n=48) were gathered from two immunotherapy appointment slots directly before and after patients with a systemic reaction.
Results: The number of systemic reactions per visit at our institution over the study period was 0.002%. Sixty six percent of patients had a grade 2 systemic reaction. Patients with systemic reactions were more likely to have had a previous systemic reaction (p = 0.0012, OR 8.6, CI 2.32-31.81) or large local reaction (p = 0.02, OR 5.5, CI 1.33-22.69) compared to the control population.
Conclusions: In our program, the major risks for a systemic reaction to immunotherapy were a prior systemic or large local reaction. Systemic reactions occurred less frequently in our program than what is reported in the literature. As part of a quality improvement initiative we demonstrated the overall safety of our immunotherapy program.